Abstract:Introduction: Melanoma has a high propensity for brain metastasis (BM). Although advancements in brain-penetrant treatments have resulted in improved central nervous system (CNS) disease control, BMs remain a significant cause of morbidity and mortality. The molecular features of melanoma BM are poorly defined, and there is an unmet need to identify biomarkers associated with CNS-specific outcomes. Methods: We retrospectively identified 109 patients with melanoma BM who underwent craniotomy at Memorial Sloan Kettering Cancer Center (MSK) between 01/2014 and 04/2023. BM specimens were sequenced using MSK-IMPACT, an FDA-approved next-generation sequencing assay covering 341-505 genes with 700X coverage. Clinical characteristics and CNS-specific outcomes were available from 107 patients; CNS-specific radiographic endpoints were verified through direct inspection of contrast-enhanced MRI imaging by a board-certified neuroradiologist. Clinical data included baseline characteristics, prior systemic or radiotherapy (RT), and CNS-directed follow up including recording local progression of disease (POD), regional POD, and development of leptomeningeal disease (LMD). Results: Majority (68%,73/107) patients were male with a median age at the time of primary diagnosis of 56 (range 3-88). Forty-eight patients (45%) had advanced disease (stages III and IV) at the time of initial diagnosis. At the time of BM development, half of the patients had 2-5 intracranial tumors present (50%) with a median diameter of largest BM of 33.4mm (range .9mm-64mm). The median KPS was 80 at the time of BM diagnosis, and 79% had neurologic symptoms prior to resection. 81 patients (76%) were treatment naïve at the time of resection and 56 patients (53%) developed CNS recurrence with the majority of those having local POD (29%,16/56) followed closely by regional POD of 1 lesion (25%,14/56). The most frequent genomic alterations in the cohort were TERT (87%), CDKN2A (50%), BRAF (43%), NRAS (28%), and PTEN (25%). The median fraction genome altered was 0.3047 and the median tumor mutational burden was 13.2 muts/Mb. We compared the genomic profiles of BM tumors of patients that had no progression, local POD, regional POD, and LMD. Compared to patients with no progression, patients with local POD were more likely to have RB1 alterations (18.1% vs 2.1%, p = 0.04, q = 0.83) and patients with LMD were less likely to have TERT alterations (62.5% vs 93.8%, p = 0.03, q = 0.75). Conclusions: Our analysis between genomic markers and clinical outcomes in melanoma BM reveals genomic features which may improve prediction and treatment strategies. Citation Format: Michel Padilla Mazzeo, Henry S. Walch, Rahul Kumar, Jordan Eichholz, Claire Cooper, Nishta Nandakumar, Junchao Shen, Ishaani Khatri, Luke Del Balzo, Anna Skakodub, Emily Miao, Daniel W. Kelly, Kenny Kwok Hei Yu, Jessica Wilcox, Brandon S. Imber, Yao Yu, Yoshiya Yamada, Harish Vasudevan, Ahmet Ilica, Nikolaus Schultz, Luke R. Pike. Clinical and genomic characterization of melanoma brain metastases [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3785.

Innv-19. Multimodal Therapy For Braf V600E Mutant Melanoma Brain Metastases: Characterization Of Chronological Treatment Strategies And Associations With Overall Survival

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients with the BRAF-V600E Mutation

Analyses of Prognostic Factors in Cases of Non-Small Cell Lung Cancer with Multiple Brain Metastases

Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer.

Real‐world Treatment and Outcomes of Patients with Metastatic BRAF Mutant Colorectal Cancer

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial Versus Standard of Care.

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways

Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center's decade of experience

Csig-29. Braf Inhibitor Therapy In Braf-Mutated Primary Brain Tumors: A Single-Center Experience

Abstract 3785: Clinical and genomic characterization of melanoma brain metastases

A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation

Transcriptome-Based Treatment for Melanoma With Brain Metastasis: A Case Report

Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience

The Effect of Non-Overlapping Somatic Mutations in BRAF, NRAS, NF1, or CKIT on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma

Current Advances in the Treatment of BRAF-Mutant Melanoma

Epid-29. Epidemiological Characterization Of Brain Metastases In Melanoma: A Large Population Based-Study From 2014-2024

Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors

Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation: A Multicenter Real-World Study in China.